Navigation Links
Survival 'excellent' following living donor liver transplantation for acute liver failure
Date:9/6/2012

Patients in Japan who underwent living donor liver transplantation (LDLT) for acute liver failure (ALF) were classified as having excellent outcomes, with ten-year survival at 73%. The findings, published in the September issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases (AASLD), suggest that the type of liver disease or treatment plan does not affect long-term patient survival following LDLT. Donor and patient age, however, does impact long-term outcome post-transplant.

According to the AASLD, roughly 2,000 Americans develop ALFformally called fulminant hepatitiseach year, with many of these cases caused by acetaminophen (Tylenol) overdose, drug-induced liver injury, autoimmune liver disease, or viral hepatitis. Previous studies report patient survival from ALF was less than 15% before the era of liver transplantation and significantly better at more than 65% following transplantation.

LDLTwhen a portion of a healthy liver from a living donor is used for transplantationwas developed as an alternative treatment option to overcome the shortage of deceased donor organs. A 2007 study by de Villa et al. found that LDLT accounts for less than 5% of liver transplants in the U.S. and Europe compared to more than 90% in Asia excluding mainland China.

"ALF is a rare, life-threatening condition where the rapid deterioration of liver function causes changes in mental activity and disrupts the body's blood clotting capabilities," explains lead author Dr. Yasuhiko Sugawara, Associate Professor in the Graduate School of Medicine at the University of Tokyo in Japan. "Expanding knowledge of treatment options, such as LDLT, that improve patient outcome is imperative."

Using data from the Intractable Liver Disease Study Group of Japan, researchers identified 209 ALF candidates who underwent living donor liver transplantation. The authors report that in patients who underwent LDLT the cumulative one-year, five-year and ten-year survival rates following transplantation were 79%, 74%, 73%, respectively. Patient age impacted short-term and long-term mortality, while donor age only affected long-term patient mortality.

"Our study demonstrates the benefit of LDLT in a Japanese population, which has less access to deceased donor organs," concludes Dr. Sugawara. "Prospective studies are needed to determine the overall impact of LDLT in all patients with ALF."

In a related editorial also published in Liver Transplantation, Professor Chung-Mau Lo with the University of Hong Kong and Queen Mary Hospital in Hong Kong, China, notes that LDLT for ALF patients has generated debate among experts in several areas: (1) reports in Western countries of inferior outcome with LDLT in high-urgency situations; (2) likelihood of ALF patients receiving a liver in countries with developed deceased organ donation programs; and (3) concern with coercion of donors and a possible increase of donor risk when the evaluation process is rushed in such an urgent situation.

"Deceased donor liver transplantation is dictated by the availability of the organ, and high-risk marginal grafts are frequently used. LDLT allows for early transplant to avoid waitlist mortality and better timing of the operation, which can be performed at the first sign of patient deterioration," concludes Professor Lo. "LDLT for ALF has developed in Asia because there is no choice. Is it possible that it may in fact be a better choice?"


'/>"/>
Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
2. Survival More Likely With Exercise-Related Cardiac Arrest: Study
3. Study examines factors associated with improvement in survival from heart attack in France
4. Survival statistics show hard fight when malignant brain tumors appear at multiple sites
5. PSA Testing Linked to Improved Prostate Cancer Survival
6. Cancer survival in Germany after the fall of the Iron Curtain
7. Prostate cancer survival rates improved since introduction of PSA testing
8. Enzalutamide adds 5 months survival in late-stage prostate cancer
9. New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
10. Study: Vaccine targets malignant brain cancer antigens, significantly lengthens survival
11. Spending more on trauma care doesnt translate to higher survival rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of ... the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient ... contributed not only to the association, but also to the Health Care Quality and ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, ... ET, http://www.fdanews.com/mdclineval                  , How will the new EU MDR language ...
(Date:3/23/2017)... ... ... and Back”: a true-life testimony of tragedy and the miraculous power of God to ... mother and grandmother committed to sharing her many spiritual adventures which affirm God’s grace ... actual events in the life of her family, which validate her deep faith in ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 2017 ReNeuron reported in December 2016 ... chronic stroke patients, despite not meeting the three-month time frame ... Action Research Arm Test (ARAT). As a result, the company ... clinical study in 2017. Beyond CTX, we expect safety and ... and Phase I data from its critical limb ischaemia (CLI) ...
(Date:3/22/2017)... -- ReportsnReports.com adds Global Vagus Nerve Stimulation ... global vagus nerve stimulation market analyst says one trend ... invasive VNS procedures. Few years ago, VNS procedures were ... high standards of healthcare infrastructure. ... Browse 30 Exhibits, ...
(Date:3/22/2017)... , March 22, 2017 Ampio ... the development of Ampion™, a low molecular weight ... today announced that it is re-issuing its previous release ... incorporate certain disclosures that are required under the ... below are these additional disclosures along with the ...
Breaking Medicine Technology: